REGISTER FOR THE 2025 CONFERENCE
Shopping Cart

No products in the cart.

SCWD Publications Digest

Staying informed on the latest in cachexia, sarcopenia, and wasting disorders research is essential yet challenging. The SCWD Digest offers concise updates and expert insights into significant studies and developments. We highlight and link directly to leading research, making it easier for healthcare professionals to access and apply groundbreaking findings. Our goal: empower the medical community to advance patient care worldwide efficiently.

AllAgeingCachexiaCancer CachexiaClinical TrialsExerciseFrailtyFrom the literatureGuidelinesMuscleNutritionOther SCWD EventsSarcopenia

Growth Differentiation Factor-15 Isย Associated With Congestion-Related Anorexia and Weight Loss in Advancedย Heartย Failure.

Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy. This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced...

๐Ÿ“ฐ Journal: Jacc-Heart Failure
Read MoreGrowth Differentiation Factor-15 Isย Associated With Congestion-Related Anorexia and Weight Loss in Advancedย Heartย Failure.

Identification of risk factors and development of a predictive nomogram for sarcopenia in Alzheimer's disease.

Sarcopenia, with its complex diagnostic process, is a likely independent predictor of poor prognosis in patients with Alzheimer's disease (AD). However, research on the clinical characteristics and biomarkers of AD patients with sarcopenia (ADSA) is limited. This study included 180...

๐Ÿ“ฐ Journal: Alzheimers & Dementia
Read MoreIdentification of risk factors and development of a predictive nomogram for sarcopenia in Alzheimer's disease.

Norharmane prevents muscle aging via activation of SKN-1/NRF2 stress response pathways.

Sarcopenia, the age-related decline in muscle mass and function, is a significant contributor to increased frailty and mortality in the elderly. Currently, no FDA-approved treatment exists for sarcopenia. Here, we identified norharmane (NR), a ฮฒ-carboline alkaloid, as a potential therapeutic...

๐Ÿ“ฐ Journal: Redox Biology
Read MoreNorharmane prevents muscle aging via activation of SKN-1/NRF2 stress response pathways.

Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions.

Sarcopenia is defined as a muscle-wasting syndrome that occurs with accelerated aging, while cachexia is a severe wasting syndrome associated with conditions such as cancer and immunodeficiency disorders, which cannot be fully addressed through conventional nutritional supplementation. Sarcopenia can be...

Read MoreSarcopenia and cachexia: molecular mechanisms and therapeutic interventions.

Metabolic interplays between the tumour and the host shape the tumour macroenvironment.

Metabolic reprogramming of cancer cells and the tumour microenvironment are pivotal characteristics of cancers, and studying these processes offer insights and avenues for cancer diagnostics and therapeutics. Recent advancements have underscored the impact of host systemic features, termed macroenvironment, on...

๐Ÿ“ฐ Journal: Nature Reviews Cancer
Read MoreMetabolic interplays between the tumour and the host shape the tumour macroenvironment.

Why are we not exploring the potential of lower limb muscle power to identify people with sarcopenia?

Sarcopenia refers to a neuromuscular disease characterized by age-related declines in muscle mass and function. Since Professor Rosenberg first introduced the concept of sarcopenia in 1989, numerous operational paradigms have been proposed, tested, and validated against negative outcomes. The most...

๐Ÿ“ฐ Journal: Ageing Research Reviews
Read MoreWhy are we not exploring the potential of lower limb muscle power to identify people with sarcopenia?

Systemic metabolic crosstalk as driver of cancer cachexia.

Cachexia is a complex metabolic disorder characterized by negative energy balance due to increased consumption and lowered intake, leading to progressive tissue wasting and inefficient energy distribution. Once considered as passive bystander, metabolism is now acknowledged as a regulator of...

๐Ÿ“ฐ Journal: Trends In Endocrinology And Metabolism
Read MoreSystemic metabolic crosstalk as driver of cancer cachexia.

Effects of digital-based interventions on the outcomes of the eligibility criteria for sarcopenia in healthy older adults: A systematic review and meta-analysis.

While the digital-based interventions targeting older adults to prevent age-related health problems such as sarcopenia have grown rapidly in recent years, there are no meta-analyses indicating synthesized pooled estimates. To examine the effects of digital-based interventions on sarcopenia-related measures, including...

๐Ÿ“ฐ Journal: Ageing Research Reviews
Read MoreEffects of digital-based interventions on the outcomes of the eligibility criteria for sarcopenia in healthy older adults: A systematic review and meta-analysis.

The microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia.

Alterations in bile acid profile and pathways contribute to hepatic inflammation in cancer cachexia, a syndrome worsening the prognosis of cancer patients. As the gut microbiota impinges on host metabolism through bile acids, the current study aimed to explore the...

๐Ÿ“ฐ Journal: Gut Microbes
Read MoreThe microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia.

Body composition alterations in patients with lung cancer.

Most patients with lung cancer experience cancer cachexia (CC), a syndrome of skeletal muscle and adipose tissue wasting. Knowledge of body composition changes in patients is limited, however, because most studies have been cross-sectional, comparing patients with non-cancer controls or...

๐Ÿ“ฐ Journal: American Journal Of Physiology-Cell Physiology
Read MoreBody composition alterations in patients with lung cancer.

Prevalence of Cachexia and Outcomes in Patients With Chronic Diseases: A National Database Analysis of 5โ€‰484โ€‰103 Hospitalisations.

Cachexia is a frequent companion of chronic diseases and a well-established predictor of poor patient performance and outcome. Since cachexia as a discharge diagnosis is not much investigated, we aimed to investigate prevalence of cachexia in hospitalised patients and their...

๐Ÿ“ฐ Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MorePrevalence of Cachexia and Outcomes in Patients With Chronic Diseases: A National Database Analysis of 5โ€‰484โ€‰103 Hospitalisations.

Weight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.

Cancer-associated cachexia can inhibit immune checkpoint inhibitor (ICI) therapy efficacy. Cachexia's effect on ICI therapy has not been studied in large cohorts of cancer patients aside from lung cancer. We studied associations between real-world routinely collected clinical cachexia markers and...

๐Ÿ“ฐ Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreWeight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.

Long-Term Impact of Physical Activity on Mortality in Adults With Multimorbidity: A 12-Year Cohort Longitudinal Study From the Survey on Health, Ageing and Retirement in Europe.

While physical activity (PA) is known to reduce mortality in the general population, this relationship in individuals with multimorbidity (โ‰ฅโ€‰2 chronic conditions) is unclear. This longitudinal study aimed to investigate whether there is a long-term association between PA levels and...

๐Ÿ“ฐ Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLong-Term Impact of Physical Activity on Mortality in Adults With Multimorbidity: A 12-Year Cohort Longitudinal Study From the Survey on Health, Ageing and Retirement in Europe.

Multiomics Analysis Reveals Therapeutic Targets for Chronic Kidney Disease With Sarcopenia.

The presence of sarcopenia in patients with chronic kidney disease (CKD) is associated with poor prognosis. The mechanism underlying CKD-induced muscle wasting has not yet been fully explored. This study investigates the influence of renal secretions on muscles using multiomics...

๐Ÿ“ฐ Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMultiomics Analysis Reveals Therapeutic Targets for Chronic Kidney Disease With Sarcopenia.

Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches.

The skeletal muscle is one of the largest organs in the body and is responsible for the mechanical activity required for posture, movement and breathing. The effects of current pharmaceutical therapies for skeletal muscle diseases are far from satisfactory; approximately...

๐Ÿ“ฐ Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!